Judit Fernández Fuertes

Judit Fernández Fuertes

Auto-generated profile, based on publicly available information

Judit Fernández Fuertes

Platelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Department of Orthopedics and Trauma Surgery, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, Spain; Dept. of Surgery and Medical Surgical Specialties, University of Oviedo, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
AAAndrea Acebes-Huerta
Andrea Acebes-Huerta
TATamara Arias-Fernández
Tamara Arias-Fernández
AGAngel Bernardo gutierrez
Angel Bernardo gutierrez
MMMaría Carmen Muñoz-Turrillas
María Carmen Muñoz-Turrillas
JFJudit Fernández-Fuertes
Judit Fernández-Fuertes
LGLaura Gutiérrez
Laura Gutiérrez

1 March 2022 in Orthopaedic Journal of Sports Medicine
Verified
Journal Article
Open access
JFJudit Fernández-Fuertes
Judit Fernández-Fuertes
TATamara Arias-Fernández
Tamara Arias-Fernández
AAAndrea Acebes-Huerta
Andrea Acebes-Huerta
MÁMarlene Álvarez-Rico
Marlene Álvarez-Rico
LGLaura Gutiérrez
Laura Gutiérrez
Background: Intra-articular infiltration of platelet-rich plasma (PRP) is an alternative therapeutic option to classic hyaluronic acid for the treatment of symptomatic knee osteoarthritis (KOA). However, variation in preparation methods and quality assessment of PRP makes the study of its real clinical efficacy difficult. Purpose: To (1) evaluate the clinical efficacy of a characterized PRP product prepared in a standardized manner and in a closed-system for the treatment of KOA and to (2) evaluate the association of the clinical response to PRP-related variables. Study Design: Case series; Level of evidence, 4. Methods: We recruited 130 patients with nonoperative KOA and evaluated them for 1 year. PRP was prepared from a donation of autologous blood, obtaining 3 aliquots of approximately 10mL of product, which were frozen, allowing platelet disruption, platelet factor release, and long-term storage, until administration. Patients were treated 3 consecutive times every 4 weeks with an intra-articular PRP knee injection under sterile conditions. Complete blood count was performed on the whole-blood sample and the processed PRP before freezing it, for product quality assessment. Patients were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and basic satisfaction scale at 3 months, 6 months, and 1 year after intervention. Results: Quality assessment confirmed a leukocyte-poor PRP product (white blood cell count, 0.09 ± 0.09 × 109/L) with a high platelet purity (platelet count, 630.86 ± 191.75 × 109/L). WOMAC scores improved, and basic satisfaction was achieved in 70% of patients. No adverse events were reported. No correlations were observed between PRP quality parameters and clinical results. PRP complete treatment production costs were €108/US$125 (€36/US$41.6 per injection). Conclusion: This standardized PRP production method resulted in improved WOMAC scores at 1 year postoperatively in 70% of patients with KOA. This technique was safe and affordable and ensured consecutive infiltrations with the same product to each patient.

1 March 2017 in Medicina Clinica
Verified
Journal Article
Closed access
JFJudit Fernández Fuertes
Judit Fernández Fuertes
ÓVÓscar Rodríguez Vicente
Óscar Rodríguez Vicente
SHSergio Sánchez Herráez
Sergio Sánchez Herráez
LPLuis Rafael Ramos Pascua
Luis Rafael Ramos Pascua

3 February 2024 in Acta Biomaterialia
Verified
Journal Article
Open access
AAAndrea Acebes-Huerta
Andrea Acebes-Huerta
PMPatricia Martínez-Botía
Patricia Martínez-Botía
GCGraciela Carbajo-Argüelles
Graciela Carbajo-Argüelles
JFJudit Fernández-Fuertes
Judit Fernández-Fuertes
MMMaría Carmen Muñoz-Turrillas
María Carmen Muñoz-Turrillas
LGLaura Gutiérrez
Laura Gutiérrez
The use and demand of platelet-based bioproducts in regenerative medicine is steadily increasing. However, it is very difficult to establish the real clinical benefits of these therapies, as the lack of characterization and detailed production methods of platelet-based bioproducts persists in the literature and precludes cross-study comparisons. We characterized the molecular composition and in vitro regenerative capacity of platelet-rich plasma (PRP) produced in a closed-system. Furthermore, we performed a parallel characterization on different PRP subfractions (plasma and plasma-free platelet lysate), identifying that the fractions containing platelet-derived cargo exert the most potent regenerative capacity. This observation led us to develop a method to obtain a platelet secretome highly enriched in growth factors, free of plasma and cellular components (PCT/IB2022/057936), with the aim of establishing a superior bioproduct. The molecular characterization of secretomes revealed agonist-dependent differences, which correlates with beneficial grades of regenerative capacity. Importantly, secretomes showed general superiority to PRP in vitro. We discuss the variables influencing the bioproduct quality (inter-donor variation, platelet source and processing methods). Finally, we propose that the characteristics of secretomes circumvents certain limitations of PRP (autologous vs allogeneic), and envision that optimizing post-processing protocols (nanoencapsulation, lyophilization), would allow their clinical application even beyond regenerative medicine. STATEMENT OF SIGNIFICANCE: The use and demand of platelet-based bioproducts in regenerative medicine is steadily increasing. However, it is very difficult to establish the real clinical benefits of these therapies, or to improve/personalize them, as the lack of characterization of the bioproducts and their production methods is a constant in the literature, reason that precludes cross-study comparisons. In the present manuscript, we provide a comprehensive molecular and functional characterization of platelet-based bioproducts and subfractions, including platelet rich plasma, plasma fractions and platelet secretomes produced with a methodology developed by our group. Our results show that the molecular composition of each fraction correlates with its regenerative capacity in vitro. Thus, a rigorous characterization of platelet-derived bioproducts will potentially allow universal use, customizing and new applications.

1 March 2017 in Medicina Clínica (English Edition)
Verified
Journal Article
Closed access
JFJudit Fernández Fuertes
Judit Fernández Fuertes
ÓVÓscar Rodríguez Vicente
Óscar Rodríguez Vicente
SHSergio Sánchez Herráez
Sergio Sánchez Herráez
LPLuis Rafael Ramos Pascua
Luis Rafael Ramos Pascua